Voronoi, Inc. · KRX:310210
Voronoi — Non-Deal Roadshow (December 2022)
27 slides from Voronoi's roadshow presentation, Dec 6, 2022
Slide 1: Non-Deal Roadshow
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design 2022.12.06 ~ 2022.12.08 Non-Deal Roadshow
Slide 2: Disclaimer
Investor Relations 2022 <> VORONOI! Disclaimer FEE 7 EAS S HYSS MAIS Presentationol|M2| Git MSS SACS Helo] FAIS|AHOlot “SIA}")Ol] fot ASIEISLICH 2] SIF OSHS BAIS BI AHPAPIS O|0 [St = Xo Bete! “SSS 71H SO! SAS 7AA| BES SSSALCh Of B17 Of Olao| Aa} Bhi! Atetoe SIA HAQORS ‘Oly, Mey, ‘AS, ICH, (©! Sz} AS
Slide 3: Content
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design CONTENT
Slide 4: Contents overview
Crea Novel Therapeutics By Pe With Excellent Expertise In Drug Design™ ® VORONOI & . Vr Drug Design Technology VORONOI Overview b= 374 7|S=40ll 7[BtSt 71S OS Sat Business Model SFE AI7i] HAITI D "MEHAelectivity)” OSA SHAI7|IS @ “b|-SErSY Sap’ [Conclusion] P7eSt MEWS & Lfsiereny Eats Pipeline Ou BWN>
Slide 5: VORONOI Overview
Investor Relations 2022 VORONOI Overview ela CHEEXE AKA FQ. ASBOF wate *OY8IPd 4: 22.0930 7 RE 2015.02. (2022.06. A!) Medchem Lab <> OrIC VORONO! = Atel ee7e (Bb | | | ~19 *20.10 21.01 21.08 21.11 *22.09 Preclinical Genter Biology Lab VORONOI 5
Slide 6: Partnerships and license-out deals
[HQ] THELIAL 71S OM Investor Relations 2022 i= ~ os xz A= OFS S74] 7| SH oll 7[btst 71S Ol/4S Att Ej MO] S Seta OFS AI7i| 7|SAl Shes! D CH7/ZCH} MO|A}ON WA D Al NS Bel Ist FI Bee HENS Hest . : PDGFRAS74 eet . HER2+/¢8Or © METIS RIPKV/A}7 -HAast et SANS S Set. 454 8.2208 USD Pan-RAF/ Ii Fue Mpsi/saer
Slide 7: Business Model
Investor Relations 2022 Business Model Discovery Eto] HAS USolo] MAag~-27 |aiet Ct7ilall 71S OM HEL O| Aop7yet BMA &EP} License-Out “sopHat SEBS Mesin UE “oat BH0| BS ME olz{n}o] SS 7H” ORB 7/24 20 HY" Discovery Capability Oz} S}S}= AIS! OIE] Over 550. 000 ivear 230,000 20M 5M 4,000 50 164,000 10,00
Slide 8: Drug design technology: selectivity
Investor Relations 2022 Ea atl 71a @ “AEH A(Selectivity)” 202014 FDA SO l=! x/BA|7| S2tSt out MENA SS OR = "SIS MEHAMO|| CLE Sa} Bare BIAAMISEAY mOt RET E}2U %1e24| Ala 71B 21EAl Cabometyx ZBPSIS (06): 28 ALZIBE EP AHB(%): 69 + ZMH PS Kinase BES Let + ZHPPSIBES (ORR): Mall BEALS S| 7/7} 30% Ok BOE S
Slide 9: Drug design technology: brain penetration
Investor Relations 2022 creel aia 71a @ “he|- SESH Ey” 7|E SS SHE +|M0| StAfoll Chet O|SS Cle LQ SOM, “BBB SUS SS ks Ai] 7/S0] UCHA, AAA 7hS” So] + -SehS Sate SE ols SOE! WIS FBO] LSPAKY Saps* roa (Kp,uu, brain) Blood ae 2A ‘Sem 100% ee %, & Blood- @5® 9 Brain 7% + SE Sl A] HOlsh= wie, + OES b|-S47t
Slide 10: Conclusion: Voronoi technology strengths
Investor Relations 2022 [Conclusion] 24+et MEH & 4] ed = BEF Top-tier +E MHS VRN11 no DYRK1A/CLK 2: Eurofins tste4 (Blood-Brain Barrier, BBB) =7}SS 7Kl Sh S24! 52 = VORONO!'s SS SSIPRY OHS >100% 71% 60~90% 50-90% | EGFR C797S_ EGFR Exon20 HER2 BRAF RIPK1(CNS) Ins. + EGFR C7975 Double Mutant, EGFR Ex
Slide 11: Pipeline
Inve: stor Relations 2022 Pipeline Bet, ELAS] Meat L|Z Soil Met Cterst SEKS| 7/BOMS olletet Target Partner Alot H|z “, AOR: 1,3008t Stay LAMaitet ORIC ren tH eel 2,1008F tet LYASE ARIAL Wet, 2k 4eslet inno.N HIE AIAfoH| Cet L7H a CBAZIO| AY HAYEIE, . jor: 5008F Tecan OBrickellbic BAB Sor seh 404 2 3
Slide 12: VRN10 HER2+
Crea Novel Therapeutics By Pe With Excellent Expertise In Drug Design™ ® VORONOI & Don HER2+ SHtot x] =A VRN10. HER2+ Introduction VRN10. HER2+ 2c so She oe VRN10. AEH VRN10. HER2+ s{eiehate! at Sutet Ae] BWNo
Slide 13: VRN10. HER2+ introduction
Investor Relations 2022 VRN10. HER2+ introduction Treatment Landscape for HER2 Positive Metastatic Breast Cancer after DBO9 clinical trial Systemic Therapy for HER2 Positive Metastatic Breast Cancer (post DBO9, 1* line setting) Systemic Therapy for HER2 Positive Metastatic Breast Cancer Taxane T-Dxd
Slide 14: VRN10 comparison with other TKIs
Investor Relations 2022 VRN10. HER2+ eye se seeace $5, UG SAHO|, | Fat YESS 71 Kt AL Rb ir a7 4| lS FOE 23S SS SHES 7\% TKls & VRN10 H|at Wild EGFR Sparing (EGFR1 CHE] EGFR2 MIEHAS) <5 <10 >100x >100x Covalent Inhibitor Non-covalent Covalent Non-covalent Covalent ue be be =] 8S BS Ss #5 LS SHHOlol|
Slide 15: VRN10 vs Neratinib and Tucatinib
Investor Relations 2022 VRN10. MEHAY Sli WS ofS0| SSOlA| Ret RO] MEAS Stet Neratinib Tucatinib BA: Euroins VORONO!I_ 15
Slide 16: VRN10 efficacy and tucatinib sales
Investor Relations 2022 VRN10. HER2+ sja2hHy = 2) SAL HH] S| Patients (%) 0) 50 40 0 SADRH suo aa i ifo 2 | Ho] SBOIAl SF 87} 1=107 1x108 Total flux [Photon/s] 5 : Internal Research Data 5 _ ae 10 15 20 Days after treatment mouse Vehicle Tucatinib (75 mpk/BID) VRN10 (10 mpk/QD) VRN10 (20 mpk/QD) 25
Slide 17: VRN11 EGFR
Crea Novel Therapeutics By Pe With Excellent Expertise In Drug Design™ ® VORONODI & ® & * ~N 8 3 Neat 1 JS VRN11. EGFR HJAAI Sot 212A] VRN11. Resistance mutations in EGFR VRN11. Technical Feasibility. in-vitro VRN11, MEHAY off-target Toxicity7} HAS] WE OMatst ORS VRN11. EGFR #A42|27| “Sere Sas VRN11
Slide 18: VRN11. Resistance mutations in EGFR
Investor Relations 2022 VRN11. Resistance mutations in EGFR VRN112 CHE OH CCE ZAC} OFS} HQ OHO EGFR SAHO| %|2Al [01] ZAHSHE CloFst Unmet Needs sZd 7ES HIAAM[SEH|2t EGFR TKls 7H2ES GBD drug ©) Unmet Needs , = >:D o Uncommon Gilotrif EGFR TKls Potency 4|i Double Mutation Drug+ #2 ) DTC ~~ LTc cis DTC
Slide 19: VRN11. Resistance mutations in EGFR
Investor Relations 2022 VRN11. Resistance mutations in EGFR lressa, Tarceva > Tagrisso 2fOl| CHE SIS Lys EGFR TKls Potency D EGFR Mutation Potency 3 D L DT LT Dc Lc ' Iressa, Tarceva D, Las & okig Sold 12} lem Se! Tagrisso2| 14} AEA] SO! OF SIE Lis Tagrisso D DC L LC VRN11 => I & @& D, Loll cSt Pote
Slide 20: VRN11. EGFR Uncommon mutation
Investor Relations 2022 VRN11. EGFR Uncommon mutation EGFR TKls Potency EGFR Mutation Potency G719X_ 1861Q s7egyy —_FX0N20 Uncommon Mutation 1%} 1274] INS 5s = THB SHES! LiCHS stat) Tagrisso Gilotrif Gilotrif VRNO7 t VRN11 (ORIC-114) 1 CriC i 4 @& EGFR Uncommon Mutationol| CHSt Potency 8! LHSPO = PL
Slide 21: VRN11. Resistance mutations in EGFR
Investor Relations 2022 VRN11. Resistance mutations in EGFR VRN112 EGFR SAHO| XA 01] ZAHSH= CoFSt Unmet Needs siZd 7kS EGFR TKls Potency H|i EGFR Mutation EGFR Uncommon Mutation Drug D L DT LT Dc Lc G L s Iressa, Tarceva Gilotrif Tagrisso VRN11 L: EGFR L858R, D: EGFR Del19, T:EGFR T790M, C: EGFR C79
Slide 22: VRN11. Off-target toxicity
Investor Relations 2022 VRN11. ATEHAS off-target Toxicity7} 31218] KES OBIS OFS QIAS BOl AMAL OBO] Setslx| RE ABO| Mew Shes OTHER ‘1: Eurofins Discover Kinomescan, 1 uM concentration top 10% cutoff, >x30-fold offtargets excluded TAT BOS S-core(10) 0.24 BIA} BS: S-core(10) 0.13 VORONO!_ 22
Slide 23: Brain distribution of EGFR TKIs
100% Mouse Rat 77.0% Table 2. Summary of healthy rat brain and CSF distribution constants, Kp and Kpuu, plus brain and plasma binding, fuplasma and fubrain, for 16 EGFR-TKIs. 75% Drug Brain Kp CSF Kp fuplasma % fubrain % Brain Kpuu CSF Kpuu Tagrisso 56.0% Osimertinib 6.09 0.0047 1.66 (0.22) 0.057 (0
Slide 24: Del19 L858R DC
0.01 0.005 Gilotrif WT 0 Del19 L858R DC LC Uncommon G719A Mutations G719C G719S
Slide 25: VRN11. Clinical Trial Study plan phase 1b expansion
Investor Relations 2022 VRN11. Clinical Trial Study plan phase 1b expansion ete AO! MEO ® Of24 EGFR SAM VRN11, Phase 1b expansion plan Ooi] CHEE Eft Stst0| 7hS' v. 3 1028 OSS ASS Combination Drug Market Size Dc -_ C7978 te |Molztat Bet Monotherapy @& Blueprint Medicines > Zai Lab BUS Cli], SS The 71
Slide 26: VRN11. NSCLC market
Investor Relations 2022 VRN11. NSCLC AJ24 HIAMEEA jet HofolA SevwHols + AGO] APR Tee Bal HAMS HBO] SAH St + THE(%) EGFR C7975 30.24 3.96 1.28) 18 40) 45,3~46.3 JIEt EGFR EGFR RET FEL O1S Cts] SO} 37H HO] EGFR SAO] SYBO| 1.6~2tH Ole SS (SH 48%, Wet 45%, SEH 43% - OF 26%, HEI 15%) HAMELS H2t2| SAHOO O
Slide 27: Thank You
Creating Novel Therapeutics By People With Excellent Expertise In Drug Design Thank You